Pierre Cordelier
Accepted Abstracts: J Cancer Sci Ther
To date, pancreatic adenocarcinoma (PDAC) can?t be diagnosed early. Consequently, a majority of patient (80%) display an advanced disease that results in a low resection rate leading to a dismal overall median survival of 4 to 6 months. This lecture will address how preclinical findings can be translated into clinical applications for treating pancreatic tumors in patients using gene therapy. Attendees of this lecture will be familiarized with the need for rigorous and stringent testing of candidate therapeutics in relevant preclinical models. Consequently, the discussion will include the description of the anticancerous genes activity, the non viral vector efficacy, the route of administration in patients and the manufacturing of the gene therapy product. In addition, we will discuss on how to carry out ancillary studies to identify non invasive diagnostic biomarkers predictive and/or indicative of treatment response and follow-up, to select clinical trial participants and/or to tailor therapy for individual patient, to create a clear prescription path for gene therapy in the forthcoming phase II clinical trial.
Pierre Cordelier has studied pancreatic cancer cell proliferation and gene therapy for more than 15 years, during which time he has authored more than 50 peerreviewed papers. He is currently the principal investigator of a INSERM research group in the Cancer Research Centre of Toulouse in Toulouse, France and the Vice-President of French Society of Gene and Cell Therapy. He is the Scientific Director of the first phase I-II gene therapy trial for pancreatic cancer using non viral vectors. He is now developing viral vectors for the therapy and exploring the use of microRNA as early molecular markers/targets for cancer.
Cancer Science & Therapy received 3968 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 